Table 4.
Pharmacokinetic parameters of harmaline in Tg-CYP2D6 and wild-type mice estimated by the pharmacogenetic-based compartmental analysis. CLCYP2D6, clearance contributed by CYP2D6-mediated metabolism; CLother, clearance contributed by other elimination pathways; CLD, distribution clearance between central and peripheral compartments; VC, volume of distribution of the central compartment; VT, volume of distribution of the peripheral compartment; Ka, absorption rate constant; F represents the bioavailability of certain dose of drug administered to different mouse models.
| Parameter | Unit | Estimated value (CV%) |
|---|---|---|
| Ka | 1/min | 0.307 (14.9) |
| VC | L/kg | 2.43 (12.1) |
| VT | L/kg | 2.86 (10.1) |
| CLD | mL/min/kg | 879 (25.3) |
| CLCYP2D6 | mL/min/kg | 60.8 (27.6) |
| CLother | mL/min/kg | 96.2 (8.68) |
| FCYP2D6, 5.mg/kg | % | 68.8 (19.5) |
| FCYP2D6, 15mg/kg | % | 80.1 (7.32) |
| FWT, 5mg/kg | % | 74.2 (15.8) |
| FWT, 15mg/kg | % | 90.3 (6.08) |